PDF(Pubmed)
Abstract：
UNASSIGNED: A retrospective clinical study was conducted to test the impact of including hyperbaric oxygen therapy in the treatment of patients with sudden sensorineural hearing loss (SSNHL).
UNASSIGNED: A total of 63 adult patients with sudden sensorineural hearing loss diagnosed between 2015 and 2023 were divided into two groups: 36 patients treated with intratympanic glucocorticoid and orally administered glucocorticoid who also underwent hyperbaric oxygen therapy and 27 patients treated with intratympanic glucocorticoid and prolonged orally administered glucocorticoid (without hyperbaric oxygen therapy). An audiological evaluation was performed using pure-tone audiometry.
UNASSIGNED: Average hearing gain as measured by pure tone average was 12.5 dB HL (+/- 19.9 dB HL) in the patients treated with steroids combined with HBOT, and was 14.1 dB HL (+/- 17.9 dB) in the patients treated with steroids alone. Successful treatment (complete recovery or marked improvement) was observed in 27.8% of the patients in the first group and in 25.5% in the second group. There was no statistically significant difference between the groups.
UNASSIGNED: Both groups of patients-those treated with glucocorticoids and those treated with glucocorticoids and HBOT-had similar hearing outcomes. A prospective, controlled, and randomized study would provide more reliable knowledge about the efficacy of HBOT in treating SSNHL.
UNASSIGNED: A total of 63 adult patients with sudden sensorineural hearing loss diagnosed between 2015 and 2023 were divided into two groups: 36 patients treated with intratympanic glucocorticoid and orally administered glucocorticoid who also underwent hyperbaric oxygen therapy and 27 patients treated with intratympanic glucocorticoid and prolonged orally administered glucocorticoid (without hyperbaric oxygen therapy). An audiological evaluation was performed using pure-tone audiometry.
UNASSIGNED: Average hearing gain as measured by pure tone average was 12.5 dB HL (+/- 19.9 dB HL) in the patients treated with steroids combined with HBOT, and was 14.1 dB HL (+/- 17.9 dB) in the patients treated with steroids alone. Successful treatment (complete recovery or marked improvement) was observed in 27.8% of the patients in the first group and in 25.5% in the second group. There was no statistically significant difference between the groups.
UNASSIGNED: Both groups of patients-those treated with glucocorticoids and those treated with glucocorticoids and HBOT-had similar hearing outcomes. A prospective, controlled, and randomized study would provide more reliable knowledge about the efficacy of HBOT in treating SSNHL.
摘要：
■进行了一项回顾性临床研究，以测试包括高压氧治疗对突发性感觉神经性听力损失（SSNHL）患者的治疗效果。
■在2015年至2023年之间诊断出的63例突发性感觉神经性听力损失的成年患者分为两组：36例接受鼓室内糖皮质激素治疗并口服糖皮质激素的患者也接受了高压氧治疗，27例接受了鼓室内糖皮质激素和长期口服糖皮质激素治疗（无高压氧治疗）。使用纯音测听法进行听力学评估。
■在接受类固醇联合HBOT治疗的患者中，通过纯音平均测量的平均听力增益为12.5dBHL（+/-19.9dBHL）。仅接受类固醇治疗的患者为14.1dBHL（/-17.9dB）。在第一组中27.8%的患者和第二组中25.5%的患者中观察到成功的治疗(完全恢复或显著改善)。组间无统计学意义差异。
■两组患者-接受糖皮质激素治疗的患者和接受糖皮质激素和HBOT治疗的患者-听力结果相似。一个潜在的，控制,随机研究将提供有关HBOT治疗SSNHL疗效的更可靠知识。
■在2015年至2023年之间诊断出的63例突发性感觉神经性听力损失的成年患者分为两组：36例接受鼓室内糖皮质激素治疗并口服糖皮质激素的患者也接受了高压氧治疗，27例接受了鼓室内糖皮质激素和长期口服糖皮质激素治疗（无高压氧治疗）。使用纯音测听法进行听力学评估。
■在接受类固醇联合HBOT治疗的患者中，通过纯音平均测量的平均听力增益为12.5dBHL（+/-19.9dBHL）。仅接受类固醇治疗的患者为14.1dBHL（/-17.9dB）。在第一组中27.8%的患者和第二组中25.5%的患者中观察到成功的治疗(完全恢复或显著改善)。组间无统计学意义差异。
■两组患者-接受糖皮质激素治疗的患者和接受糖皮质激素和HBOT治疗的患者-听力结果相似。一个潜在的，控制,随机研究将提供有关HBOT治疗SSNHL疗效的更可靠知识。
